

Will Vaccine-derived Protective Immunity Curtail COVID-19 Variants in the US?

Marina Mancuso[◇], Steffen E. Eikenberry[◇], Abba B. Gumel^{◇◆}

July 14, 2021

[◇] *School of Mathematical and Statistical Sciences, Arizona State University, Tempe, Arizona, 85287, USA.*

[◆] *Other Affiliation: Department of Mathematics and Applied Mathematics, University of Pretoria, Pretoria 0002, South Africa.*

Abstract

Multiple effective vaccines are currently being deployed to combat the COVID-19 pandemic (caused by SARS-COV-2), and are viewed as the major factor in marked reductions in disease burden in regions around the world with moderate to high coverage of these vaccines. The effectiveness of COVID-19 vaccination programs is, however, significantly threatened by the emergence of new SARS-COV-2 variants that, in addition to being more transmissible and potentially more virulent than the wild (resident) strain, may at least partially evade existing vaccines. A new two-strain (one resident, the other wild) and two-group (vaccinated or otherwise) mechanistic mathematical model is designed and used to assess the impact of the vaccine-induced cross-protective efficacy on the spread the COVID-19 pandemic in the United States. Analysis of the model, which is fitted using COVID-19 mortality data for the US, shows that vaccine-induced herd immunity can be achieved if 61% of the American population is fully vaccinated with the Pfizer or Moderna vaccines. Parameter sensitivity analysis suggests three main factors that significantly affect the COVID-19 burden in the US, namely (a) daily vaccination rate, (b) the level of cross-protection the vaccines offer against the variant, and (c) the relative infectiousness of the dominant variant relative to the wild strain. This study further suggests that a new variant can cause a significant disease surge in the US if (i) the vaccine coverage against the wild strain is low (roughly $< 50\%$), (ii) the variant is much more transmissible (e.g., twice more transmissible) than the wild-type strain, or (iii) the level of cross-protection offered by the vaccine is relatively low (e.g., less than 70%). A new variant will not cause such surge in the US if it is only moderately more transmissible (e.g., 56% more transmissible) than the wild strain, at least 66% of the population of the US is fully vaccinated, and the three vaccines being deployed in the US (Pfizer, Moderna, and Johnson & Johnson) offer a moderate level of cross-protection against the variant.

Keywords: *COVID-19; vaccine; wild-strain; variant; reproduction number; herd immunity.*

Corresponding Author Email: agumel@asu.edu

1 Introduction

Since its emergence late in December 2019, the novel coronavirus pandemic (COVID-19), caused by the RNA virus SARS-COV-2, has spread to every corner of the world. While other coronavirus pandemics have emerged in recent decades, (including the 2002-2004 severe acute respiratory syndrome (SARS-CoV-1) and the 2012-present middle eastern respiratory syndrome (MERS-CoV) pandemics [1]), COVID-19 represents the greatest global public health challenge since the 1918-1919 influenza pandemic. As of June 18, 2021, there have been over 176 million confirmed COVID-19 cases and over 3.8 million deaths worldwide, with the US the most affected county (with over 33 million confirmed cases and now over 600,000 COVID-19 deaths), although cases and deaths may be dramatically under-counted in some communities or jurisdictions [31].

40 The most common symptoms of COVID-19 disease include dry cough, shortness of breath, fever, fatigue,
41 muscle aches, and loss of taste or smell. Symptoms develop roughly 2-14 days after contacting the SARS-CoV-
42 2 virus, likely via respiratory droplets or aerosols, and typically last for up to two weeks, although a minority
43 experience “long COVID-19,” when symptoms endure for several weeks or months, and interfere with day-to-day
44 life [2]. The severity of symptoms varies widely from wholly asymptomatic disease to severe multi-organ system
45 failure and death. Risk of a poor outcome increases with comorbidities, such as immunocompromised status, heart
46 or lung disease, diabetes, etc., while the mortality rate increases exponentially with age. Transmission to susceptible
47 individuals peaks early in the natural history of the disease, with infected individuals infectious several days before
48 the onset of symptoms (pre-symptomatic stage); those who never develop symptoms may also still pass the disease
49 as asymptomatic carriers [14].

50 Until late December 2020, control and mitigation measures against COVID-19 in the US were exclusively non-
51 pharmaceutical interventions (NPIs), such as the quarantine of those suspected of being exposed to the disease,
52 isolation of individuals with disease symptoms, community “lockdowns,” social (physical)-distancing, and the use
53 of face masks [3–5, 54, 55, 66]. Numerous states and jurisdictions within the US have implemented lockdown and
54 mask mandates of varying strictness and duration to limit COVID-19 spread [41–49, 51].

55 The US Food and Drugs Administration (FDA) gave emergency use authorization (EUA) for the first vaccine
56 against COVID-19 on December 11, 2020 [27, 28], developed by Pfizer-BioNtech and based on delivery of RNA
57 (mRNA) encoding the SARS-CoV-2 spike protein [6]. Two doses of the vaccine administered 21 days apart showed
58 95% efficacy against symptomatic COVID-19 in clinical trials including 44,000 participants [27, 28]. A week later
59 (December 18, 2020), the FDA authorized a vaccine developed by Moderna Inc. [29]. This vaccine is also based
60 on mRNA technology. Delivered in two doses four weeks apart, the vaccine showed efficacy of 94.5% and in
61 initial clinical trials [29]. The most recent vaccine to receive EUA (February 27, 2021) is the Janssen vaccine,
62 developed by Johnson & Johnson and administered in a single dose [30]. Unlike the mRNA-based Pfizer and
63 Moderna vaccines, the Johnson & Johnson vaccine was developed using adenovirus vector encoding the SARS-
64 CoV-2 spike protein. Results from clinical trials have shown the Johnson & Johnson vaccine to be 67% effective
65 in preventing moderate to severe COVID-19 14 days post-vaccination [30]. Although the vaccines have generally
66 only been available to those 16 and older (Pfizer) or 18 and older (Moderna, J&J), but the FDA recently extended
67 EUA for the Pfizer vaccine to be administered to children of ages 12–15 [69].

68 Following EUA in December 2020, limited vaccine doses were made available according to prioritization
69 schedules that varied somewhat by state, but generally prioritized the elderly, healthcare workers, and long-term
70 care residents [34]. Vaccination rates generally increased nearly linearly since then for several months, but have
71 since peaked and are on the decline as of June 2021. Even with all individuals aged 12 and above now eligible to
72 receive the Pfizer vaccine in the US, increasing vaccine coverage is now widely viewed as a problem of limited
73 demand rather than supply. While vaccines are highly effective against the original SARS-CoV-2 strain, sustainable
74 control of the COVID-19 epidemic may hinge on the characteristics of emerging variant strains.

75 Viruses are subject to mutations when replicating, and mutations that increase the fitness of the virus tend to
76 persist in the population. In fact, by the middle of March 2020, the dominant SARS-CoV-2 strain in the US has
77 already mutated from the original strain that emerged in Wuhan, China three months earlier [20]. Since then,
78 several additional variants from the original SARS-CoV-2 strain have appeared around the globe [19] with many
79 likely more transmissible than the original SARS-CoV-2 strain [21, 23], and possibly more deadly. For instance,
80 the B.1.1.7 variant first appeared in the United Kingdom during late summer of 2020 [21], and may be associated
81 with an increased risk of disease-induced death [19]. The mutations of this variant were found on the spike protein
82 of the SARS-CoV-2 virus [36]. This variant was first detected in the US on December 29, 2020 in Colorado [24].
83 The B.1.1.7. variant was shown to be 56% more transmissible than the wild-type (original) SARS-CoV-2 strain
84 [23]. Individuals with the B.1.1.7. variant were 1.4 times more likely to be hospitalized, and 1.58-1.71 times
85 more likely to die from COVID-19 complications [22]. Another variant, B.1.351, emerged independently from the
86 B.1.1.7. variant, but shares some similar mutations [19]. The B.1.351 variant was first identified in South Africa
87 in October 2020, and was detected in the US at the end of January 2021 [25]. Furthermore, the P.1. variant of the
88 SARS-CoV-2 virus has 17 unique mutations, with origins tracing back to Brazil. This variant also appeared in the
89 US at the end of January 2021 [26]. Finally, the most recent VOC to have emerged in the US is the B.1.617.2 that

90 first appeared in India.

91 Other SARS-CoV-2 variants have appeared in RNA sequencing, but the B.1.1.7, P.1, and B.1.351 variants
92 represent the greatest proportion of variants currently circulating in the US and are currently classified as variants
93 of concern (VOC) [35, 36]. VOCs have shown evidence of (i) more disease rapid spread, (ii) more severe disease,
94 (iii) evading current diagnostic tests, and/or (iv) resistance to naturally-acquired or vaccine-induced immunity when
95 compared to the wild-type SARS-CoV-2 strain, which does not contain any major mutations [17, 19, 36]. These
96 concerns are compounded by the fact that, as more individuals are vaccinated, mask mandates and social-distancing
97 measures are being relaxed, or fully-lifted altogether [40, 50, 52]. SARS-CoV-2 strains sequenced in the US during
98 the middle of May 2021 showed the B.1.1.7 variant accounting for nearly 70% of the variants sequenced, 8.1%
99 of the variants were identified as P.1, and 2.5% for variant B.1.617.2 [35]. It can be reasonably assumed that the
100 reported cases of COVID-19 caused by variants underestimates the number of true cases. The B.1.617.2 variant,
101 for example, is estimated to be responsible for 6% of US cases, and as much as 18% for some states [71]. This
102 is due to the limited genomic sequencing capabilities and strain surveillance, when compared to the magnitude of
103 infection transmission. Although several government-operated, university affiliated, and independent laboratories
104 throughout the US sequence several thousand strains of the SARS-CoV-2 virus each week, this still amounts to less
105 than 1% of total infections reported [19].

106 Recent studies regarding the cross-protective immunity of existing vaccines on the SARS-CoV-2 VOCs have
107 shown varying results [17, 18, 38, 39]. Some studies evaluating the cross-efficacy of the Pfizer-BioNtech vaccine
108 on the B.1.1.7 and B.1.351 variants showed no significant differences of antibody neutralization when two doses of
109 the vaccine were delivered 18-28 days apart [38, 39]. However, for those who acquired immunity through infection
110 recovery (convalescent immunity) or only received a single dose of the vaccine, less neutralizing antibodies were
111 produced, particularly for the B.1.351 variant [39, 72]. Another study compared the cross-efficacy of the B.1.1.7
112 and B.1.351 variants when two doses of the Moderna vaccine was administered 28 days apart [17], which showed
113 reduction in antibody neutralization for the B.1.351 strain, but not the B.1.1.7 strain. Further research is needed to
114 validate and confirm these initial reports.

115 Despite the uncertainty regarding the level of cross-efficacy that current EUA vaccines provide against VOCs,
116 some researchers showed that there is, at least, some degree of cross-protection [16, 19]. However, it is of major
117 public health interest to understand how new variants can, in principle, impact the community, and if the current
118 vaccination program will be enough to eliminate the pandemic in the United States, under a plausible range of
119 scenarios with respect to variant transmissibility and cross-protection.

120 During the earliest days of the COVID-19 pandemic, before extensive experimental or case data was available,
121 mathematical modeling was a useful tool to gauge the severity and potential impact that the disease would have
122 on the community [3–5, 54–66]. With the increased availability and administration of the Pfizer, Moderna, and
123 Johnson & Johnson vaccines in the US, as well as uncertainties surrounding the recently emerged SARS-CoV-2
124 variants, mathematical modeling can be a very useful tool to estimate the extent cross-protective immunity from
125 vaccines protect the community from the emerging COVID-19 variants. The current study uses a novel mathemat-
126 ical model to assess the impact of vaccination and vaccine-induced cross-protection against the B.1.1.7 and other
127 SARS-CoV-2 variants circulating in the US as of June 2021. The two-strain and two-group model, which takes the
128 form of a deterministic system of nonlinear differential equations, is formulated in Section 2. The model is fitted
129 using COVID-19 mortality data, and a key unknown parameter of the model was estimated from the fitting. Further,
130 basic qualitative features of the model, including the derivation of vaccine-derived herd immunity threshold for the
131 US and parameter sensitivity analysis, are discussed in Section 3. Numerical simulations are presented in Section
132 4.

133 2 Model Formulation

134 In this section, the new two-strain, two-group mechanistic model for the transmission dynamics of two SARS-CoV-
135 2 strains (the wild-type and variant strains) in the presence of vaccination, is formulated. The total population of
136 individuals in the community at time t , denoted by $N(t)$, is stratified into two groups based on vaccination status,

137 namely the total unvaccinated group, denoted by $N_U(t)$ and the total vaccinated group denoted by $N_V(t)$, so that
138 $N(t) = N_U(t) + N_V(t)$. The total unvaccinated population ($N_U(t)$) is further stratified into the mutually-exclusive
139 compartments of individuals that are unvaccinated susceptible (S_U), latent or "exposed" (E_i), pre-symptomatically
140 infectious (P_i), symptomatically infectious (I_i), asymptotically infectious (A_i), hospitalized (H_i), and recovered
141 (R_i), with $i = 1, 2$ (represents the SARS-CoV-2 strain), so that

$$N_U(t) = S_U(t) + \sum_{i=1}^2 [E_i(t) + P_i(t) + I_i(t) + A_i(t) + H_i(t) + R_i(t)]. \quad (2.1)$$

142 Similarly, the total vaccinated population ($N_V(t)$) is sub-divided into the sub-populations of individuals that are
143 vaccinated susceptible ($S_V(t)$), exposed (E_{Vi}), pre-symptomatically infectious (P_{Vi}), symptomatically infectious
144 (I_{Vi}), asymptotically infectious (A_{Vi}), hospitalized (H_{Vi}), and recovered (R_{Vi}), with $i = 1, 2$. Thus,

$$N_V(t) = S_V(t) + \sum_{i=1}^2 [E_{Vi}(t) + P_{Vi}(t) + I_{Vi}(t) + A_{Vi}(t) + H_{Vi}(t) + R_{Vi}(t)]. \quad (2.2)$$

145 Vaccinated individuals are assumed to have received the full required doses (i.e., they are fully vaccinated). The
146 equations for the rate of change of the aforementioned state variables of the two-strain, two-group vaccination
147 model for COVID-19 transmission dynamics and control in the US are given by the deterministic system of non-
148 linear differential equations in Equation (A-1) of Appendix A. The flow diagram of the model is depicted in Figure
149 1, and the state variables and parameters of the model are described in Tables A.7 and A.8, respectively.

150 In the formulation of the model (A-1), we assume a setting where two strains of SARS-CoV-2 are co-circulating
151 in the population: strain 1, the wild-type (original) strain that is assumed to be the predominant strain circulating
152 the US throughout 2020 [20] and strain 2, a new dominant, variant strain assumed to be circulating in the US since
153 the end of 2020 [24]). For mathematical tractability and convenience, we assume that susceptible individuals can
154 be infected with either of the two strains, but not with both. Further, we have no real evidence for co-infection
155 of multiple SARS-CoV-2 strains at the current moment. The three EUA vaccines in the US (i.e., the Pfizer, Mod-
156 erna, and Johnson & Johnson vaccines) target the wild-type strain with efficacy ε_v , and are assumed to induce
157 cross-protective efficacy (ε_c) against the dominant variant (strain 2) [17, 18, 38, 39]. Vaccination is offered to all
158 eligible unvaccinated individuals, but for simplicity, the model does not consider vaccination of currently infected
159 individuals (symptomatic or asymptomatic). In other words, the model only considers vaccinating those who are
160 wholly-susceptible and those who recovered from the disease prior to being vaccinated. Although currently infec-
161 tious individuals may be getting vaccinated, they comprise of extremely small fraction of the overall population at
162 any given time, and are not included (for simplicity).

163 Some of the other main assumptions made in the formulation of the model (A-1) include the following:

- 164 (i) Homogeneous mixing: the population is well-mixed, such that every member of the community is equally
165 likely to mix with every other member of the community. Further, the waiting times in each epidemiological
166 compartment are exponentially distributed [67].
- 167 (ii) Because of the inherent age structure in the COVID-19 vaccine administration (where, in the context of the
168 Pfizer vaccine, for instance, only people at age 12 or older are vaccinated [28]), we include demographic
169 (birth and death) parameters to account for the inflow of new susceptible individuals that are eligible for
170 vaccination.
- 171 (iii) Vaccination is only offered to wholly-susceptible individuals or those who naturally recovered from COVID-
172 19 infection (but not for currently-infected individuals).
- 173 (iv) Vaccinated individuals are assumed to have received the full recommended dosage (two doses for Pfizer or
174 Moderna vaccine, one dose for the Johnson & Johnson vaccine), and that the vaccine administered was stored
175 at the appropriate temperatures, and that enough time has elapsed for the body to develop immunity.

- 176 (v) The vaccines are imperfect against infection (i.e, breakthrough infection can occur) [28–30]. The vaccines
 177 offer strong therapeutic benefits, *vis a vis* reducing severe disease, hospitalization, and death [28–30].
- 178 (vi) Vaccine-derived and natural immunity may wane over time in individuals, in which they revert to the wholly-
 179 susceptible class.




Figure 1: Schematic diagram of the model (A-1).

180 2.1 Data Fitting and Parameter Estimation

181 In this section, the model (A-1) is fitted using the cumulative mortality data from Johns Hopkins’ Center for
 182 Systems Science & Engineering (from January 22, 2020 to March 6, 2021) [31] and daily vaccination data from
 183 Bloomberg (from December 21, 2020 to March 6, 2021) [32] for the US. Fitting is used to estimate the contact rate
 184 parameter for the wild-type strain (strain 1), β_1 , during each wave of the COVID-19 pandemic in the US [31, 32].
 185 The fitting is done in the absence of vaccination for the period from January 22, 2020 to January 21, 2021, and
 186 including vaccination for January 22, 2021 to March 6, 2021. We use a MATLAB routine to minimize the sum of
 187 squared differences between each observed cumulative mortality data point and the corresponding mortality point
 188 obtained from the model (A-1). COVID-19 mortality data, rather than case data, is used to fit the model since it is
 189 more reliable (the latter underestimates the true number of cases owing to the inability to track asymptomatic and
 190 pre-symptomatic cases, resulting from the absence of random wide-scale testing across the US) [14].

191 The first case of the B.1.1.7 variant was documented in the US on December 29, 2020 [?], although the variant
 192 was likely introduced to the US prior to detection. For the actual fitting, we introduce 1,000 cases of a variant strain
 193 (i.e., $I_2(0) = 1,000$) on December 29, 2020 to estimate variant infections present prior to confirmation of its US
 194 detection. Further, vaccination is introduced in the model (A-1) on January 21, 2021. Since our model does not
 195 explicitly consider the two-dose vaccine structure or account for any delay from inoculation to (partial) immunity,
 196 we introduce a delay from actual to modeled vaccination by constructing an inferred second dose time-series. That
 197 is, the available data only gives total doses delivered and does not disaggregate between first and second doses.
 198 Therefore, we assume that during the first 30 days of vaccine reporting, all administered doses are first doses. After
 199 30 days, all first doses result in a second dose, and any remaining doses for that day are considered first doses. An

200 inferred second dose time series can thus be constructed iteratively. Second doses were roughly 35% of the total
 201 doses administered each day following the first four weeks of vaccination [32].




Figure 2: (a) Fitting of the model (A-1) using cumulative mortality data for the US [31]. (b) Simulations of the model (A-1) using the fixed and estimated parameters, given in A.9 and strain 1 contact rate values from Table 1, illustrating the daily mortality generated from the model, in comparison to the observed daily mortality data for the US. For both panel, initial conditions used were $S_U(0) = 336$ million, $I_1(0) = 10$ and all other state variables set at zero. The purple vertical line shows the time that 1,000 cases of the variant strain (strain 2) was introduced in the population (December 29, 2020), and assumed to be 1.56 times as infectious as strain 1 [23]. The brown vertical line shows the time at which vaccination was introduced into the model (January 22, 2021) using data from [32].

202 Furthermore, the following expression was used to determine the time-dependent vaccination rate, $\alpha_v(t)$:

$$\alpha_v(t) = \frac{\text{estimated vaccination (second) doses on day } t}{S_U(t) + R_1(t) + R_2(t)}. \quad (2.3)$$

203 This expression allows for the realistic possibility that individuals who have recovered from infection (and may
 204 have naturally-acquired immunity against future infection) will be vaccinated along with susceptible individuals.
 205 Thus, a proportion of the vaccination doses administered each day are delivered to wholly-susceptible individuals
 206 who have not developed prior COVID-19 immunity.

207 The result of the data fitting of the model (A-1), using the fixed parameters in Table A.9, is depicted in Figure 2.
 208 The left panel of this figure shows the model (A-1) fit using the observed cumulative US mortality data. The right
 209 panel shows the simulations of the model (A-1) with the fixed and fitted parameters, compared to the observed daily
 210 mortality data for the US. The purple vertical dotted line in each panel indicates the time that a variant strain was

introduced into the US population (December 29, 2020). The contact rate for the variant strain, (β_2) was assumed to be 1.56 times greater than the contact rate for the wild-type strain (β_1) [23]. The brown dotted lines indicate the time when vaccination was introduced into the population (January 21, 2021). The model (A-1) with the chosen fixed parameter values fits well with the observed cumulative and daily US COVID-19 death data.

Table 1: Results from fitting the contact rate, β_1 , to cumulative COVID-19 death data for the US with model (A-1) for the COVID-19 pandemic from January 22, 2020 to March 6, 2021.

Pandemic Period	β_1	Time Frame
First wave	0.3742	Jan 22, 2020 - April 1, 2020
Lockdown period	0.0726	April 2, 2020 - June 15, 2020
Second wave	0.1494	June 16, 2020 - July 20, 2020
Post-second wave	0.0864	July 21, 2020 - Sept 18, 2020
Third wave	0.1421	Sept 19, 2020 - Jan 6, 2021
Post-third wave	0.0805	Jan 6, 2021 - March 6, 2021

The contact rate, β_1 , varies throughout the course of the pandemic due to implementation and compliance of non-pharmaceutical interventions (NPIs) and vaccination. Table 1 shows the values of the contact rate for the wild-type strain (strain 1), β_1 , for each period of the pandemic. The first wave of the COVID-19 pandemic (January 22, 2020 to April 1, 2020) was the period with the highest contact rate, and occurred prior to most wide-scale NPI implementation (particularly the CDC’s recommendation of face mask usage). The lockdown period (April 2, 2020 to June 15, 2020) was the period when numerous US states implemented stay-at-home policies, and was shown to have a lower contact rate. The second wave, which occurred during the early to mid summer of 2020 (June 16, 2020 to July 20, 2020) and was period when many states stay-at-home orders expired and businesses started returning to operation. This resulted in a higher contact rate, which in turn lead to more observed COVID-19 mortality. Many states began tightening restrictions on businesses again after seeing the rise in cases and deaths, which resulted in the post-second wave period (July 21, 2020 to September 18, 2020) having a decreased contact rate. As states lifted business restrictions and other COVID-19 related NPIs in mid-September, 2020 [52], and many Americans traveled for the holidays, a large third wave of the pandemic was observed for September 19, 2020 to January 6, 2021, that had a similar contact rate as the second wave. As vaccination distribution commenced towards the final weeks of 2020, the contact rate once again decreased to a level similar to the post-second wave contact rate. We note that during the second and third waves, most US states still maintained a baseline level of NPI implementation and compliance (e.g., social distancing polices, face mask mandates). Thus, the contact rates for the second and third waves were not as high as the initial pandemic wave.

3 Mathematical Analysis: Computation of Reproduction Number

In this section, the reproduction number of the model (A-1) is computed for the special case where the vaccination rate, $\alpha_v(t)$, is treated as constant. That is, We consider the *autonomous* version of the model with $\alpha_v(t) = \alpha_v$, a constant. The autonomous version of the model (A-1) has a unique disease-free equilibrium (DFE) given by

$$\mathbb{E}_0 = (S_U^*, S_V^*, E_1^*, E_{V1}^*, P_1^*, P_{V1}^*, I_1^*, I_{V1}^*, A_1^*, A_{V1}^*, H_1^*, H_{V1}^*, R_1^*, R_{V1}^*, E_2^*, E_{V2}^*, P_2^*, P_{V2}^*, I_2^*, I_{V2}^*, A_2^*, A_{V2}^*, H_2^*, H_{V2}^*, R_2^*, R_{V2}^*),$$

where $S_U^* = \frac{\Pi(\omega_v + \mu)}{\mu(\omega_v + \alpha_v + \mu)}$, $\frac{\Pi\alpha_v}{\mu(\omega_v + \alpha_v + \mu)}$ and all other components of \mathbb{E}_0 are zero. The *next generation operator method* [7, 8] can be used to analyze the local asymptotic stability of the DFE (\mathbb{E}_0). Noting that $N^* = S_U^* + S_V^*$, and using the notation in [7], it follows that the non-negative matrix (F) of new infection terms, and the matrix (M) of new transition terms, are, respectively, given by:

$$F = \begin{pmatrix} F_1 & \mathbf{0}_{10 \times 10} \\ \mathbf{0}_{10 \times 10} & F_2 \end{pmatrix} \text{ and } M = \begin{pmatrix} M_1 & \mathbf{0}_{10 \times 10} \\ \mathbf{0}_{10 \times 10} & M_2 \end{pmatrix}.$$

238 where the matrices F_1 , F_2 , M_1 and M_2 are given in Appendix B, and $\mathbf{0}_{10 \times 10}$ denotes the zero matrix of order 10. It
 239 follows that the *vaccination reproduction number* of the autonomous version of the model (A-1), denoted by \mathcal{R}_{vac} ,
 240 is given by (where ρ denotes the spectral radius of the next generation matrix FM^{-1})

$$\mathcal{R}_{vac} = \rho(FM^{-1}) = \max\{\mathcal{R}_{vac}^{[1]}, \mathcal{R}_{vac}^{[2]}\}, \quad (3.1)$$

241 where $\mathcal{R}_{vac}^{[1]}$ and $\mathcal{R}_{vac}^{[2]}$ (given in Appendix B) represent, respectively, the constituent reproduction numbers associ-
 242 ated with the transmission of strains 1 and 2. The result below follows from Theorem 2 of [7].

243 **Theorem 3.1.** *The DFE (\mathbb{E}_0) of the autonomous version of the model (A-1) is locally-asymptotically stable if*
 244 *$\mathcal{R}_{vac} < 1$, and unstable if $\mathcal{R}_{vac} > 1$.*

245 The threshold quantity, \mathcal{R}_{vac} , measures the average number of new COVID-19 cases generated by a single in-
 246 fectious individual introduced into a population where a certain proportion is vaccinated. The epidemiological
 247 implication of Theorem 3.1 is that a small influx of COVID-19 cases will not generate an outbreak in the commu-
 248 nity if the *vaccination reproduction number* (\mathcal{R}_{vac}) is brought to (and maintained at) a value less than unity.

249 3.1 Computation of the Herd Immunity Threshold

250 Herd immunity, which is a measure the fraction of susceptible individuals that need to be protected against infection
 251 in order to eliminate community transmission of an infectious disease, can be attained through two main ways:
 252 natural recovery from infection or from vaccination. However, the safest and fastest way to achieve herd immunity
 253 is through vaccination [9, 10]. Furthermore, at least 15% of the U.S. population currently cannot be vaccinated
 254 due to age restrictions [37]. Additionally, individuals who are pregnant, breastfeeding, have underlying medical
 255 conditions, as well as for other reasons, may be unable or unwilling to be vaccinated against COVID-19. Thus,
 256 it is critical to know what minimum proportion of the susceptible US population need to be vaccinated to achieve
 257 herd immunity (so that the pandemic can be effectively controlled). In this section, we derive the expression for
 258 achieving herd immunity against COVID-19 in the US based on widespread vaccination against the wild-type
 259 SARS-CoV-2 strain (i.e., strain 1).

260 In the absence of vaccination and other public health interventions (e.g., social-distancing, mask wearing, etc),
 261 the *vaccination reproduction number* (\mathcal{R}_{vac}) reduces to the *basic reproduction number* (denoted by \mathcal{R}_0) given
 262 below:

$$\mathcal{R}_0 = \mathcal{R}_v |_{S_v^* = \varepsilon_v = \alpha_v = 0} = \max\{\mathcal{R}_1, \mathcal{R}_2\}, \quad (3.2)$$

263 where \mathcal{R}_1 and \mathcal{R}_2 are the constituent *basic reproduction numbers* for the wild-type (strain 1) and the variant (strain
 264 2) SARS-CoV-2 strains, respectively, given by (where k_i , with $i = 1, 2, \dots, 20$ are given in Appendix B):

$$\mathcal{R}_1 = \frac{\beta_1[\eta_{P1}k_5k_7k_9\sigma_1 + k_7k_9r\xi_1\sigma_1 + \eta_{A1}k_5k_9(1-r)\xi_1\sigma_1 + \eta_{H1}k_7r\xi_1\phi_1\sigma_1]}{k_1k_3k_5k_7k_9},$$

$$\mathcal{R}_2 = \frac{\beta_2[\eta_{P2}k_{15}k_{17}k_{19}\sigma_2 + k_{17}k_{19}q\xi_2\sigma_2 + \eta_{A2}k_{15}k_{19}(1-q)\xi_2\sigma_2 + \eta_{H2}k_{17}q\xi_2\phi_2\sigma_2]}{k_{11}k_{13}k_{15}k_{17}k_{19}}.$$

265 For the case when all individuals in the population are vaccinated, the constituent reproduction numbers for the
 266 wild-type (strain 1) and variant (strain 2) SARS-CoV-2 strains become:

$$\mathcal{R}_{v_1} = \frac{\beta_1(1 - \varepsilon_v)\theta_v(Q_1 + Q_2 + Q_3 + Q_4)}{k_2k_4k_6k_8k_{10}} \text{ and } \mathcal{R}_{v_2} = \frac{\beta_2(1 - \varepsilon_c)\theta_c(Q_5 + Q_6 + Q_7 + Q_8)}{k_{12}k_{14}k_{16}k_{18}k_{20}},$$

267 where expressions for $Q_i, i = 1, 2, \dots, 8$ are also given in Appendix B. Hence, for the case where all individuals in
268 the population are vaccinated, the expression for the vaccination reproduction number of the model is given by:

$$\mathcal{R}_v = \max\{\mathcal{R}_{v_1}, \mathcal{R}_{v_2}\}. \quad (3.3)$$

269 It follows that the *vaccination reproduction numbers* of wild-type (strain 1, $\mathcal{R}_{vac}^{[1]}$) and variant (strain 2, $\mathcal{R}_{vac}^{[2]}$) can
270 be re-written in terms of their *basic reproduction numbers* \mathcal{R}_1 and \mathcal{R}_2 , and reproduction numbers when the entire
271 population is vaccinated, as below:

$$\mathcal{R}_{vac}^{[1]} = \mathcal{R}_1 \left[1 - f_v \left(1 - \frac{\mathcal{R}_{v_1}}{\mathcal{R}_1} \right) \right] \text{ and}$$

$$\mathcal{R}_{vac}^{[2]} = \mathcal{R}_2 \left[1 - f_v \left(1 - \frac{\mathcal{R}_{v_2}}{\mathcal{R}_2} \right) \right],$$

272 where $f_v = \frac{S_V^*}{N^*}$ is the proportion of susceptible individuals in the community who have been vaccinated (at steady-
273 state). The herd immunity threshold is computed by setting $\mathcal{R}_{vac}^{[1]} = 1$ and solving for f_v (noting that it is necessary
274 to ensure, in this computation, that $0 < \mathcal{R}_{v_1} \leq 1 < \mathcal{R}_1$). Doing so gives:

$$f_v = \frac{\mathcal{R}_1}{\mathcal{R}_1 - \mathcal{R}_{v_1}} \left(1 - \frac{1}{\mathcal{R}_1} \right) = f_{v_1}^c. \quad (3.4)$$

275 Using the fixed parameters in Table A.9 and a contact rate of $\beta_1 = 0.24$ to account for transmission in the absence
276 of nonpharmaceutical control measures (face mask usage, social distancing policies), the herd immunity threshold
277 for the wild-type (strain 1) SARS-CoV-2 strain is 0.61 for the Pfizer or Moderna vaccines ($\varepsilon_v = 0.94$), and 0.86
278 using the Johnson & Johnson vaccine ($\varepsilon_v = 0.67$). Thus, 61% of community members must be vaccinated if all
279 individuals use the Pfizer or Moderna vaccines, or 86% of community members if the Johnson & Johnson vaccine
280 is used.

281 3.2 Parameter Sensitivity Analysis

282 The model (A-1) contains numerous parameters, and uncertainties arise in the estimated values of some of the
283 parameters (e.g., those related to vaccination and dynamics of variants) used in the numerical simulations. In this
284 section, sensitivity analysis is carried out, using Latin Hypercube Sampling (LHS) and Partial Rank Correlation
285 Coefficients (PRCC) [12, 13, 68], to determine the parameters that have the highest influence on the value of the
286 chosen response function. Sensitivity analysis measures the extent that a response function changes with respect to
287 variations in the input variables. For this study, the *vaccination reproduction number* for the variant strain ($\mathcal{R}_{vac}^{[2]}$)
288 was used as the response function. One thousand bootstrap sample iterations were used for the LHS, and PRCC
289 determined the correlation each individual parameter has on the response function ($\mathcal{R}_{vac}^{[2]}$). The baseline value
290 of the contact rate, β_2 was chosen as 0.24, with additional baseline values for fixed parameters from Table A.9.
291 The PRCC values generated for the parameters in the expression of the response function, $\mathcal{R}_{vac}^{[2]}$, are tabulated in
292 Table 2. The contact rate of the variant strain (β_2), the fraction of non-vaccinated and vaccinated individuals who
293 experience symptomatic infection from the variant strain (q, q_v), and the modification parameter (η_{A2}) accounting
294 for relative infectiousness of non-vaccinated asymptomatic individuals infected with the variant strain compared
295 to non-vaccinated asymptomatic individuals infected with the wild-type strain have the greatest PRCC magnitude.




Figure 3: Contour plot of the vaccination reproduction number ($\mathcal{R}_{vac}^{[1]}$) for the wild-type (strain 1) of the model (A-1), as a function of vaccine coverage at steady-state (f_v) and vaccine efficacy (ϵ_v) for the US. Parameter values used in this simulation are as given in Table A.9, with the contact rate set at $\beta_1 = 0.24$.

296 That is, β_2 , q , q_v , and η_{A2} most affect the *vaccination reproduction number* of the variant strain ($\mathcal{R}_{vac}^{[2]}$), and, thus,
 297 the dynamics of the model (A-1).

Table 2: PRCC values for the parameters of the model (A-1), using the *vaccination reproduction number* of the variant strain, $\mathcal{R}_{vac}^{[2]}$. Parameter values that most affect the dynamics of the model are highlighted in bold font.

Parameter	PRCC	Parameter	PRCC
β_2	0.3410	ϕ_2	-0.0048
ϵ_c	-0.05	ϕ_{V2}	-0.0365
η_{P2}	0.0213	f_v	-0.0478
η_{PV2}	0.0738	μ	0.0047
η_{A2}	0.1109	γ_{I2}	-0.0710
η_{AV2}	0.0367	γ_{IV2}	-0.0957
η_{H2}	0.0589	γ_{A2}	-0.0422
η_{HV2}	-0.0057	γ_{AV2}	-0.0863
σ_2	-0.0058	γ_{H2}	-0.0620
σ_{V2}	-0.0150	γ_{HV2}	-0.0130
q	0.2682	δ_{I2}	0.0202
q_v	0.2142	δ_{IV2}	0.0372
ξ_2	0.0122	δ_{H2}	-0.0452
ξ_{V2}	-0.0329	δ_{HV2}	-0.0485

298 4 Numerical Simulations: Assessment of Vaccination Program

299 The model (A-1) is now simulated using the fixed parameters in Table A.9 to assess the population-level impact of
300 the emerging variant on the dynamics of COVID-19. Simulations for the US are carried out for the period March 6,
301 2021 to March 6, 2023 for two levels of variant strain transmissibility in relation to the wild-type strain: Scenario 1
302 assumes the variant strain is 1.56 times transmissible (i.e., B.1.1.7 variant [20]), and Scenario 2 assumes the variant
303 strain is twice as transmissible. The values of each model compartment on the last point of the fitting period on
304 March 6, 2021 (see Section 3) were used as initial conditions to simulate projections of future COVID-19 dynamics
305 in the U.S. The contact rate for the wild-type strain was chosen to be 0.0805 from March 6, 2021 to March 30,
306 2021 (i.e., the result of fitting the post-third wave period, see Table A.9) and increased to 0.161 on April 1, 2021
307 to account for the alleviation of face mask mandates and social distancing policies in various states [40, 50]. Each
308 Scenario is assessed for three levels of vaccination coverage: 50%, 66%, and 75% (i.e., $f_v = 0.5, 0.66$, and 0.75).
309 Simulations are carried out assuming vaccinated individuals receive both doses of the Pfizer/Moderna vaccine
310 ($\varepsilon_v = 0.94$).

311 Due to inconclusive data surrounding the length of vaccine and naturally-acquired immunity, we assume for
312 the period of simulation that previously infected individuals remain in their respective recovered classes. This as-
313 sumption is consistent with other COVID-19 modeling studies [3–5, 15, 54, 55]. Thus, results using administration
314 of the Johnson & Johnson vaccine are not shown, since the assumption that individuals will not become re-infected
315 during the simulation period results in an overall lower COVID-19 compared to administering the Pfizer/Moderna
316 vaccines. In other words, under administration of the less efficacious Johnson & Johnson vaccine ($\varepsilon_v = 0.67$), more
317 individuals will become infected with the less deadly wild-type strain rather than the more deadly variant strain.
318 Furthermore, since less than 8% of fully-vaccinated individuals in the US have received the Johnson & Johnson
319 vaccine [70], simulations under Pfizer/Moderna vaccine administration can better estimate the future course of the
320 pandemic.

321 4.1 Scenario 1: Variant is 1.56 times more transmissible than wild-type strain

322 Data from [20] suggests that the B.1.1.7. variant is 1.56 times more transmissible (i.e., 1.56 times more infectious)
323 than the wild-type strain in the US. Here, we simulate the dynamics of the two strains under this assumption,
324 for various levels of full-vaccination coverage (50%, 66%, 75%) and cross-protective vaccination efficacy ($\varepsilon_c =$
325 $0, 0.25, 0.5, 0.7$) offered by the Pfizer/Moderna vaccines. Cumulative COVID-19 related deaths and cases for
326 Scenario 1 are tabulated in Table 3, and values and occurrence of the peak daily COVID-19 related deaths and
327 new infections are included in Table 4.

328 The absolute worst-case-scenario for the population would be if the vaccines do not offer any cross-protection
329 (i.e., if $\varepsilon_c = 0$). Fortunately, the three EUA vaccines currently used in the US do offer a significant level cross-
330 protective efficacy against existing variants [16, 19]. However, it is helpful to quantify how much morbidity and
331 mortality burden from the variant strain could be averted through cross-protection. Table 3 shows that, under the
332 worst-case scenario, nearly half of the US population would have acquired infection, causing over two million
333 deaths. Roughly 73% of cases and deaths would be caused by the variant strain. The peak daily burden would be
334 experienced during mid September 2021, with over 2 million new cases per day.

335 If 50% of the US population became fully-vaccinated, then as much as 192,000 to 918,000 lives can be saved
336 under 25% to 70% cross-protective vaccination efficacy. If vaccination coverage is increased to 75%, then 3 to
337 14.8 million deaths can be averted. At a moderately-high level of cross-protective efficacy ($\varepsilon_c = 0.7$), then even
338 vaccination coverage levels as low as 66% can avoid another pandemic wave. Figure 4 shows the simulations of
339 Scenario 1 when 75% of the US population is fully vaccinated with the Pfizer/Moderna vaccines.




Figure 4: Simulation projections of model (A-1) from January 22, 2020 to March 6, 2023 for Scenario 1 in the U.S: Pfizer/Moderna vaccine ($\epsilon_v = 0.94$), 75% vaccination coverage, and variant strain 1.56 times as infectious as the wild-type strain. Additional parameter values are included in Table A.9. (a) cumulative COVID-19 mortality, (b) daily COVID-19 mortality, (c) cumulative COVID-19 infections, (d) new daily COVID-19 infections. The red dots represent the reported data points from [31], the dark blue curve indicates the model fit from Section 3, the red curve shows the projections assuming no cross-protective efficacy of the variant strain (strain 2) from the vaccine ($\epsilon_c = 0$), the green curve shows projections assuming a low amount of cross-protective efficacy ($\epsilon_c = 0.25$), the light blue curve shows projections assuming a moderate amount of cross-protective efficacy ($\epsilon_c = 0.5$) and the purple curve shows the projections assuming a moderately-high amount of cross-protective efficacy ($\epsilon_c = 0.7$). The purple dashed vertical line for each panel indicates the time the variant strain was introduced into the population (December 29, 2020), and the brown dashed vertical line represents the time vaccination was introduced into the model (January 21, 2021).

Table 3: Cumulative COVID-19 related deaths and infections simulated by the model (A-1) under Scenario 1 for varying levels of cross-protective vaccination efficacy of the vaccine against the variant strain (ϵ_c) and vaccination coverage (f_v) as of March 6, 2023 in the US. Scenario 1 assumes vaccinated individuals receive two doses of the Pfizer or Moderna vaccines ($\epsilon_v = 0.94$) and that the variant strain is 1.56 times as infectious as the wild-type strain.

ϵ_c	f_v	Cumulative Deaths ($\times 10^5$)		Cumulative Infections ($\times 10^6$)	
		Both Strains	Variant Strain	Both Strains	Variant Strain
0	0.5-0.75	20.47	14.9	167.5	122.0
	0.5	18.55	12.98	151.9	106.3
0.25	0.66	17.80	12.23	145.7	100.2
	0.75	17.44	11.81	142.2	96.7
0.5	0.5	15.23	9.67	124.7	79.07
	0.66	12.69	7.13	103.9	58.36
0.7	0.75	10.96	5.38	89.6	44.1
	0.5	11.29	5.71	92.45	46.0
0.7	0.66	5.62	0.006	46.04	0.46
	0.75	5.58	0.0007	45.65	0.059

Table 4: The peak of daily COVID-19 related deaths and infections simulated by the model (A-1) under Scenario 1 for various levels of cross-protective vaccination efficacy of against the variant strain (ϵ_c) and vaccination coverage (f_v). Scenario 1 assumes vaccinated individuals receive two doses of the Pfizer or Moderna vaccines ($\epsilon_v = 0.94$) and that the variant strain is 1.56 times as infectious as the wild-type strain. A dashed line “-” indicates that the simulation did not produce a peak of infections or deaths during the course of simulation.

ϵ_c	f_v	Peak of Daily Deaths ($\times 10^3$)		Peak of Daily New Infections ($\times 10^5$)	
		Date	Number	Date	Number
0	0.5-0.75	Sept 24, 2021	23.1	Sept 14, 2021	22.2
	0.5	Nov 5, 2021	16.1	Oct 23, 2021	14.7
0.25	0.66	Nov 18, 2021	13.8	Nov 3, 2021	12.4
	0.75	Nov 25, 2021	12.6	Nov 13, 2021	11.2
0.5	0.5	Jan 21, 2022	8.45	Jan 8, 2022	7.30
	0.66	April 16, 2022	4.21	April 3, 2022	3.54
	0.75	July 5, 2022	2.36	June 20, 2022	1.96
0.7	0.5	June 16, 2022	3.07	May 30, 2022	2.57
	0.66	—————	—	—————	—
	0.75	—————	—	—————	—

340 4.2 Scenario 2: Variant is twice as transmissible as wild-type strain

341 If we assume now that the variant is, instead, twice as transmissible as the wild-type strain in the US, the worst-
342 case-scenario ($\epsilon_c = 0$) would cause an additional 214,000 cumulative deaths and 17.6 million cases than the worst
343 case from Scenario 1. The peak of daily cases and deaths would shift 9 weeks earlier to late July 2021 and exceed
344 3.76 million new cases a day. If 50% of the US population is fully vaccinated, 23.5 to 35.5 million more cases
345 and 300,000 to 432,000 more deaths may occur when compared to the same vaccination coverage under Scenario
346 1. An additional 17.6 to 44.1 million cumulative cases and 214,000 to 537,000 cumulative deaths will occur under
347 75% vaccination coverage when compared to Scenario 1. With a more infectious variant strain, even high levels of
348 vaccination coverage (75%) and cross-protective vaccination efficacy ($\epsilon_c = 0.7$) will result in a future pandemic
349 wave. Figure 5 shows the simulations of Scenario 2 when 75% of the US population is fully vaccinated with the
350 Pfizer/Moderna vaccines. Cumulative COVID-19 related deaths and cases for Scenario 2 are tabulated in Table 5,
351 and values and occurrence of the peak daily COVID-19 related deaths and new infections are included in Table 6.




Figure 5: Simulation projections of model (A-1) from January 22, 2020 to March 6, 2023 for Scenario 2 in the U.S: Pfizer or Moderna vaccine ($\varepsilon_v = 0.94$) and 75% vaccination coverage with variant strain (strain 2) being twice as infectious as the wild-type strain (strain 1). Additional parameter values are included in Table A.9. (a) cumulative COVID-19 mortality, (b) daily COVID-19 mortality, (c) cumulative COVID-19 infections, (d) new daily COVID-19 infections. The red dots represent the reported data points, the dark blue curve indicates the model fit from Section 3, the red curve shows the projections assuming no cross-protective efficacy of the variant strain (strain 2) from the vaccine ($\varepsilon_c = 0$), the green curve shows projections assuming a low amount of cross-protective efficacy ($\varepsilon_c = 0.25$), the light blue curve shows projections assuming a moderate amount of cross-protective efficacy ($\varepsilon_c = 0.5$) and the purple curve shows the projections assuming a moderately-high amount of cross-protective efficacy ($\varepsilon_c = 0.7$). The purple dashed vertical line for each panel indicates the time when variant cases were introduced into the US population (December 29, 2020), and the brown dashed vertical line represents the time vaccination was introduced into the model (January 21, 2021).

Table 5: Cumulative COVID-19 related deaths and infections simulated by the model (A-1) under Scenario 2 for varying levels of cross-protective vaccination efficacy against the variant strain (ε_c) and vaccination coverage (f_v) as of March 6, 2023 in the US. Scenario 2 assumes that vaccinated individuals receive two doses of the Pfizer or Moderna ($\varepsilon_v = 0.94$) and that the variant strain is twice as infectious as the wild-type strain.

ε_c	f_v	Cumulative Deaths ($\times 10^5$)		Cumulative Infections ($\times 10^6$)	
		Both Strains	Variant Strain	Both Strains	Variant Strain
0	0.5-0.75	22.61	17.04	185.1	139.5
	0.5	21.43	15.86	175.4	129.8
0.25	0.66	20.98	15.42	171.8	126.2
	0.75	20.74	15.17	169.8	124.2
0.5	0.5	19.02	13.44	155.7	110.1
	0.66	17.35	11.79	142.1	96.49
0.7	0.75	16.33	10.76	133.7	88.10
	0.5	15.61	10.03	127.8	82.14
0.7	0.66	11.88	6.31	92.28	51.69
	0.75	9.24	3.72	76.06	30.31

Table 6: The peak daily COVID-19 related deaths and infections from March 6, 2021 to March 6, 2023 simulated by the model (A-1) under Scenario 2 varying levels of cross-protective vaccination efficacy against the variant strain (ε_c) and vaccination coverage (f_v). Scenario 2 assumes vaccination individuals receive two doses of the Pfizer or Moderna vaccines ($\varepsilon_v = 0.94$) and that the variant strain is twice as infectious as the wild-type strain.

ε_c	f_v	Peak Daily Deaths ($\times 10^3$)		Peak Daily New Infections ($\times 10^5$)	
		Date	Amount	Date	Amount
0	0.5-0.75	July 29, 2021	35.5	July 19, 2021	37.91
	0.5	Aug 17, 2021	28.40	Aug 7, 2021	28.55
0.25	0.66	Aug 21, 2021	26.03	Aug 10, 2021	25.64
	0.75	Aug 22, 2021	24.80	Aug 10, 2021	24.16
	0.5	Sept 16, 2021	19.24	Sept 4, 2021	18.11
0.5	0.66	Oct 4, 2021	13.75	Sept 22, 2021	12.38
	0.75	Oct 13, 2021	10.90	Oct 1, 2021	9.59
	0.5	Oct 26, 2021	11.04	Oct 13, 2021	9.85
0.7	0.66	Jan 3, 2022	3.98	Dec 22, 2022	3.35
	0.75	March 30, 2022	1.30	March 13, 2022	1.08

352 Discussion and Conclusions

353 Since the emergence of COVID-19 in Wuhan, China late 2019, the COVID-19 pandemic has ravaged the world
 354 by infecting every country and altered life as we know it. Fortunately, scientists and researchers have swiftly
 355 developed several vaccines to combat the virus using mRNA (Pfizer and Moderna) and adenovirus (Johnson &
 356 Johnson) technology. Over 2.23 billion shots have been administered worldwide as of June 18, 2021 and over 43%
 357 of the US population is fully vaccinated [33, 70]. However, recent variants of SARS-CoV-2 have emerged and
 358 become a public health concern, particularly: the B.1.1.7 variant first discovered in the UK, the B.1.351 variant
 359 initially found in South Africa, the P.1 variant that originated from Brazil, and the B.1.617.2 variant from India have
 360 infected numerous countries, including the US. Current data and studies show strong evidence that these variants
 361 are more easily transmissible and have higher rates of hospitalization and disease-induced death. The greatest
 362 concern of the variants is the inconclusive cross-protective efficacy from the current COVID-19 vaccines available.

363 Numerous studies have investigated the impact of COVID-19 on different populations through mathematical
 364 modeling techniques. These studies include statistical [59–61], mechanistic/deterministic [15, 53–55], stochastic
 365 [56–58], network [62–64], and agent based [65, 66] modeling types. This study presents a novel deterministic
 366 system of 26 nonlinear differential equations to assess the cross-protective efficacy of vaccination on SARS-CoV-2
 367 variant strains. We used known parameter values for the wild-type strain and open-access COVID-19 death data to
 368 estimate the contact rate for infection transmission throughout the course of the pandemic in the United States. The
 369 two-strain model (A-1) includes vaccination of susceptible and naturally recovered individuals, and its autonomous
 370 equivalent is shown to have an asymptotically stable disease free equilibrium (DFE) when the *vaccination repro-*
 371 *duction number* (\mathcal{R}_{vac}) is less than unity. The *vaccination reproduction number* measures the total amount of
 372 new infections that result from a single infection in a partially protected population, and an explicit expression for
 373 \mathcal{R}_{vac} is derived, along with the expression for the herd immunity threshold (f_v^c). The herd immunity threshold
 374 measures the fraction of susceptible community members that must acquire immunity through vaccination, in the
 375 U.S. population to halt the COVID-19 pandemic. Additionally, the parameters most sensitive to the *vaccination*
 376 *reproduction number* of the variant strain ($\mathcal{R}_{vac}^{[2]}$) were found to be the variant strain contact rate (β_2), the proportion
 377 of individuals (non-vaccinated and vaccinated) who experience symptoms from infection with the variant strain (q ,
 378 q_v), and the modification parameter (η_{A2}) that accounts for relative infectiousness of non-vaccinated asymptomatic
 379 individuals infected with the variant strain compared to non-vaccinated asymptomatic individuals infected with the
 380 wild-type strain. Finally, the model (A-1) was numerically simulated for four different Scenarios with varying vac-

381 cine efficacy (ε_v) of the wild-type strain, cross-protective vaccination efficacy (ε_c) of the variant strain, successful
382 vaccination coverage level (f_v), and relative transmission rate of the variant strain compared to the wild-type strain.

383 The worst case occurs when there is no level of cross-protective vaccination efficacy against the variant (i.e., if
384 $\varepsilon_c = 0$). The worst case predicts that 49.85% of the U.S. population will have acquired infection by the March 6,
385 2023, over 2 million individuals would have lost their lives from COVID-19, and 72.5% of cases and COVID-19
386 related deaths resulting from a variant strain that is 1.56 times as infectious as the wild-type strain. If the variant
387 ends up being twice as infectious as the wild-type strain, then as much as 55% of the U.S. population will have
388 been infected with COVID-19 by March 6, 2023, with now more than 2.2 million COVID-19 related deaths, and
389 75.4% of the pandemic burden being caused by the variant strain.

390 Wide-scale vaccination is essential to eliminating the pandemic and reducing the overall COVID-19 burden.
391 The vaccination coverage level, cross-protective vaccination efficacy against variant strains, and the relative in-
392 fectionousness of the variant strain when compared to the wild-type strain all greatly influence the dynamics of the
393 model (A-1). Both cross-protective vaccination efficacy against the variant and vaccination coverage shift the peak
394 of daily cases and deaths forward in time with increasing levels. The peak of daily deaths is expected to occur
395 approximately 10 to 16 days after the peak of daily infections occurs.

396 No data is currently available about if, or how much infectiousness is reduced by vaccinated individuals. There-
397 fore, this study assumes that vaccinated individuals, when infected, are equally likely to transmit infection as non-
398 vaccinated individuals ($\theta_v = \theta_c = 1$). This study also assumes that exclusive deployment of the Pfizer or Moderna
399 vaccines in the simulations. In reality, there's a combination of individuals receiving the Johnson & Johnson ver-
400 sus the Pfizer or Moderna vaccines, with each possibly having a different level of cross-protective efficacy against
401 variant strains and therapeutic effects (e.g., increased recovery rates, decreased disease-related death rates). More-
402 over, another limitation of the current framework of the model (A-1) is that it can only analyze one variant strain
403 of SARS-CoV-2. Extension of this model could include multiple variant strains to determine the individual and
404 collective impact on the COVID-19 pandemic. Since current studies show that naturally-acquired immunity is less
405 likely to produce an immune response to the existing variants than vaccination [18, 39], another future extension of
406 the model (A-1) could include the possibility that individuals who recovered from the wild-type strain (R_1 class)
407 could be directly infected by the variant strain without losing developed immunity from the wild-type strain. This
408 would alter the *vaccination reproduction number* and *basic reproduction number* expressions of the model (A-1).

409 The B.1.1.7 is currently the most dominant variant circulating in the US population [19, 35], and estimated
410 to be 56% more infectious than the wild-type strain [23]. The numerical simulations showed that if a moderate
411 level of vaccination coverage ($\geq 66\%$ of the US population) and moderately-high level of cross-protective vac-
412 cination efficacy ($\varepsilon_c \geq 0.7$) is attained, then a surge of variant-induced COVID-19 infections and mortality will
413 not occur (under the assumption that both vaccine and naturally-acquired immunity lasts at least two years). One
414 study showed that cross-protective efficacy is as high as 93% against the B.1.1.7 variant when two doses of the
415 Pfizer vaccine are administered, but drops to 33% when only one dose is received [71]. If the variant is much more
416 transmissible than the wild-type strain, then even at moderately high levels of cross-protective efficacy ($\varepsilon_c = 0.7$)
417 and vaccine coverage (75% of the US population), the U.S. could still experience a severe wave of COVID-19
418 cases caused by variant strains that will be detrimental to the community. Numerical simulations show that if the
419 US experiences another wave of infections, the peak daily COVID-19 related deaths and new cases are almost
420 exclusively from the variant strain. This could result in another period of lockdown and exacerbate morbidity and
421 mortality from the virus. Despite many states relieving COVID-19 related restrictions and face mask mandates
422 now that vaccination has become more widely available [40, 50], it imperative that we continue to follow non-
423 pharmaceutical intervention (NPI) protocol. Further, the risk of the B.1.617.2 variant that recently emerged in the
424 US has had devastating consequences in South Asia, and we are wait to see how the transmission of this variant
425 unfolds in the US. Current studies show that the full recommended dosage of the Pfizer vaccine is 88% against the
426 B.1.617.2 variant [71]. Thus, it is critical to encourage all eligible individuals to receive the full two dose regimen
427 of the Pfizer or Moderna vaccines.

428

429

430 **Declaration of Competing Interests**

431 The authors declare no competing interests.

432 **5 Appendix A**

433 **5.1 Equations of the mathematical model**

434 The two-strain, two-group vaccination model for the COVID-19 transmission dynamics and control in the US is
435 given by the following deterministic system of nonlinear differential equations:

$$\begin{aligned}
 \frac{dS_U}{dt} &= \Pi + \omega_v S_V + \psi_1 R_1 + \psi_2 R_2 - \lambda_1 S_U - \lambda_2 S_U - \alpha_v(t) S_U - \mu S_U \\
 \frac{dS_V}{dt} &= \alpha_v(t) S_U + \psi_{V1} R_{V1} + \psi_{V2} R_{V2} - (1 - \varepsilon_v) \lambda_1 S_V - (1 - \varepsilon_c) \lambda_2 S_V - (\omega_v + \mu) S_V \\
 \frac{dE_1}{dt} &= \lambda_1 S_U - (\sigma_1 + \mu) E_1 \\
 \frac{dE_{V1}}{dt} &= (1 - \varepsilon_v) \lambda_1 S_V - (\sigma_{V1} + \mu) E_{V1} \\
 \frac{dP_1}{dt} &= \sigma_1 E_1 - (\xi_1 + \mu) P_1 \\
 \frac{dP_{V1}}{dt} &= \sigma_{V1} E_{V1} - (\xi_{V1} + \mu) P_{V1} \\
 \frac{dI_1}{dt} &= r \xi_1 P_1 - (\phi_1 + \gamma_{I1} + \mu + \delta_{I1}) I_1 \\
 \frac{dI_{V1}}{dt} &= r_v \xi_{V1} P_{V1} - (\phi_{V1} + \gamma_{IV1} + \mu + \delta_{IV1}) I_{V1} \\
 \frac{dA_1}{dt} &= (1 - r) \xi_1 P_1 - (\gamma_{A1} + \mu) A_1 \\
 \frac{dA_{V1}}{dt} &= (1 - r_v) \xi_{V1} P_{V1} - (\gamma_{AV1} + \mu) A_{V1} \\
 \frac{dH_1}{dt} &= \phi_1 I_1 - (\gamma_{H1} + \mu + \delta_{H1}) H_1 \\
 \frac{dH_{V1}}{dt} &= \phi_{V1} I_{V1} - (\gamma_{HV1} + \mu + \delta_{HV1}) H_{V1} \\
 \frac{dR_1}{dt} &= \gamma_{I1} I_1 + \gamma_{A1} A_1 + \gamma_{H1} H_1 - \alpha_v(t) R_1 - (\psi_1 + \mu) R_1 \\
 \frac{dR_{V1}}{dt} &= \alpha_v(t) R_1 + \gamma_{IV1} I_{V1} + \gamma_{AV1} A_{V1} + \gamma_{HV1} H_{V1} - (\psi_{V1} + \mu) R_{V1} \\
 \frac{dE_2}{dt} &= \lambda_2 S_U - (\sigma_2 + \mu) E_2 \\
 \frac{dE_{V2}}{dt} &= (1 - \varepsilon_c) \lambda_2 S_V - (\sigma_{V2} + \mu) E_{V2} \\
 \frac{dP_2}{dt} &= \sigma_2 E_2 - (\xi_2 + \mu) P_2 \\
 \frac{dP_{V2}}{dt} &= \sigma_{v2} E_{V2} - (\xi_{V2} + \mu) P_{V2} \\
 \frac{dI_2}{dt} &= q \xi_2 P_2 - (\phi_2 + \gamma_{I2} + \mu + \delta_{I2}) I_2 \\
 \frac{dI_{V2}}{dt} &= q_v \xi_{V2} P_{V2} - (\phi_{V2} + \gamma_{IV2} + \mu + \delta_{IV2}) I_{V2} \\
 \frac{dA_2}{dt} &= (1 - q) \xi_2 P_2 - (\gamma_{A2} + \mu) A_2 \\
 \frac{dA_{V2}}{dt} &= (1 - q_v) \xi_{V2} P_{V2} - (\gamma_{AV2} + \mu) A_{V2} \\
 \frac{dH_2}{dt} &= \phi_2 I_2 - (\gamma_{H2} + \mu + \delta_{H2}) H_2 \\
 \frac{dH_{V2}}{dt} &= \phi_{V2} I_{V2} - (\gamma_{HV2} + \mu + \delta_{HV2}) H_{V2} \\
 \frac{dR_2}{dt} &= \gamma_{I2} I_2 + \gamma_{A2} A_2 + \gamma_{H2} H_2 - \alpha_v(t) R_2 - (\psi_2 + \mu) R_2 \\
 \frac{dR_{V2}}{dt} &= \alpha_v(t) R_2 + \gamma_{IV2} I_{V2} + \gamma_{AV2} A_{V2} + \gamma_{HV1} H_{V1} - (\psi_{V2} + \mu) R_{V2}
 \end{aligned} \tag{A-1}$$

436

437 5.1.1 Description of parameters of the model

438 The parameter Π is the recruitment rate (via birth or immigration) of individuals into the population. Individuals
 439 are vaccinated at a time-dependent rate $\alpha_v(t)$. The vaccine is assumed to produce protective efficacy $0 < \varepsilon_v < 1$
 440 against strain 1, potential cross-protective efficacy $0 \leq \varepsilon_c < 1$ against strain 2, and wane at rate ω_v . Natural death
 441 occurs in all epidemiological classes at rate μ . Susceptible individuals acquire infection with strain 1 at a rate λ_1
 442 or with strain 2 at a rate λ_2 , where

$$\lambda_1 = \beta_1 \left[\frac{I_1 + \eta_{P1}P_1 + \eta_{A1}A_1 + \eta_{H1}H_1 + \theta_v(I_{V1} + \eta_{PV1}P_{V1} + \eta_{AV1}A_{V1} + \eta_{HV1}H_{V1})}{N} \right], \quad (\text{A-2})$$

443 and,

$$\lambda_2 = \beta_2 \left[\frac{I_2 + \eta_{P2}P_2 + \eta_{A2}A_2 + \eta_{H2}H_2 + \theta_c(I_{V2} + \eta_{PV2}P_{V2} + \eta_{AV2}A_{V2} + \eta_{HV2}H_{V2})}{N} \right]. \quad (\text{A-3})$$

444 In (A-2) and (A-3), β_i (with $i = 1, 2$) is the effective contact rate for strain i , η_{Pi} (η_{Pvi}), η_{Ai} (η_{Avi}), and η_{Hi} (η_{Hvi})
 445 are, respectively, the modification parameters accounting for the assumed increase or reduction of contact rates of
 446 unvaccinated (vaccinated) pre-symptomatic, asymptomatic, and hospitalized individuals with strain i , compared to
 447 symptomatic infectious individuals with strain i . The modification parameter $0 \leq \theta_v \leq 1$ represents the assumed
 448 reduced infectiousness of individuals vaccinated against strain 1 (in comparison to unvaccinated infectious individ-
 449 uals with strain 1), while ($0 \leq \theta_c \leq 1$) accounts for the assumed reduced infectiousness of strain 2 induced by the
 450 cross-protective of vaccination against strain 1.

451 Unvaccinated (vaccinated) individuals in the exposed classes (strain 1 or strain 2) progress to their respective
 452 strain's pre-symptomatic class at rate σ_i (σ_{vi}) where $i = \{1, 2\}$ indicates the strain of infection. Non-vaccinated
 453 (vaccinated) individuals transition out of the pre-symptomatic classes at rate ξ_i (ξ_{vi}). For strain 1, fraction $0 <$
 454 r (r_v) < 1 of individuals develop symptoms while $(1 - r)$ ($(1 - r_v)$) individuals remain asymptomatic infectious.
 455 The fraction of un-vaccinated (vaccinated) individuals infected with strain 2 who develop symptoms is $0 < q$ (q_v) $<$
 456 1 . Non-vaccinated (vaccinated) symptomatic infectious individuals recover at rate γ_{Ii} (γ_{Ivi}), become hospitalized
 457 at rate ϕ_i (ϕ_{vi}), and die from disease-induced death at rate δ_{Ii} (δ_{Ivi}). Non-vaccinated (vaccinated) asymptomatic
 458 infectious individuals recover at rate γ_{Ai} (γ_{Avi}). Non-vaccinated (vaccinated) Hospitalized individuals recover at
 459 rate γ_{Hi} (γ_{Hvi}) and die from disease-induced death rate δ_{Hi} (δ_{Hvi}). Non-vaccinated (vaccinated) individuals lose
 460 their naturally-acquired disease-induced immunity at rate ψ_i (ψ_{vi}).

461 5.2 Table of state Variables and parameters of the model

462 The state variables and parameters of the model are described in Tables A.7 and A.8, respectively.

Table A.7: Description of variables of model (A-1) where ($i = 1, 2$) indicates the strain of infection.

Variable ($i = 1, 2$)	Interpretation
S_U (S_V)	Population of unvaccinated (vaccinated) susceptible individuals
E_i (E_{Vi})	Population of unvaccinated (vaccinated) individuals exposed to (latently infected with) strain i
P_i (P_{Vi})	Population of unvaccinated (vaccinated) pre-symptomatic infectious individuals infected with strain i
I_i (I_{Vi})	Population of unvaccinated (vaccinated) symptomatic infectious individuals infected with strain i
A_i (A_{Vi})	Population of unvaccinated (vaccinated) asymptomatic infectious individuals infected with strain i
H_i (H_{Vi})	Population of unvaccinated (vaccinated) hospitalized infectious individuals infected with strain i
R_i (R_{Vi})	Population of unvaccinated (vaccinated) individuals who naturally recovered from strain i infection

Table A.8: Description of parameters of model (A-1) where $(i = \{1, 2\})$ indicates the strain of infection.

Parameter ($i = 1, 2$)	Interpretation
Π	Recruitment rate into the population via birth or immigration
β_i	Infectious contact rate of individuals infected with strain i
$\eta_{Pi} (\eta_{Ai}, \eta_{Hi})$	Modification parameter to account for relative infectiousness of unvaccinated pre-symptomatic (asymptomatic, hospitalized) individuals infected with strain i
$\eta_{PVi} (\eta_{AVi}, \eta_{HVi})$	Modification parameter to account for relative infectiousness of vaccinated pre-symptomatic (asymptomatic, hospitalized) individuals infected with strain i
$0 \leq \theta_v (\theta_c) \leq 1$	Modification parameter to account for reduced infectiousness of vaccinated individuals infected with strain 1 (strain 2)
$\alpha_v(t)$	<i>Per capita</i> vaccination rate
ω_v	Waning rate of vaccine
$\psi_i (\psi_{Vi})$	Rate of loss of disease-acquired immunity for unvaccinated (vaccinated) individuals infected with strain i
μ	Natural death rate
$0 \leq \varepsilon_v \leq 1$	Vaccination efficacy against the wild-type strain (strain 1)
$0 \leq \varepsilon_c \leq 1$	Vaccination cross-protective efficacy against the variant strain (strain 2)
$\xi_i (\xi_{Vi})$	Progression rate from unvaccinated (vaccinated) exposed (latently infected) individuals infected with strain i to pre-symptomatic class
$0 < r (r_v) < 1$	Fraction of unvaccinated (vaccinated) infectious individuals infected with strain 1 who develop clinical symptoms of COVID-19
$0 < q (q_v) < 1$	Fraction of unvaccinated (vaccinated) infectious individuals infected with strain 2 who develop symptoms
$\phi_i (\phi_{Vi})$	Hospitalization rate of unvaccinated (vaccinated) symptomatic infectious individuals infected with strain i
$\gamma_{Ii} (\gamma_{Ai}, \gamma_{Hi})$	Recovery rate of unvaccinated symptomatic infectious (asymptomatic infectious, hospitalized) individuals infected with strain i
$\gamma_{IVi} (\gamma_{AVi}, \gamma_{HVi})$	Recovery rate of vaccinated symptomatic infectious (asymptomatic infectious, hospitalized) individuals infected with strain i
$\delta_{Ii} (\delta_{IVi})$	Disease-induced death rate of unvaccinated (vaccinated) symptomatic infectious individuals infected with strain i
$\delta_{Hi} (\delta_{HVi})$	Disease-induced death rate of unvaccinated (vaccinated) hospitalized individuals infected with strain i

463 **5.3 Values of fixed parameters**

Table A.9: Fixed parameters of the model (A-1) for data fitting and simulations.

Parameter	Value	Source	Parameter	Value	Source	Parameter	Value	Source
Π	12,000	[55]	μ	3.5×10^{-5}	[55]	γ_{I2}	0.1	[4, 15]*
η_{P1}	1.25	[55]	σ_1	0.40	[4, 55]	γ_{IV2}	0.1	[4, 15]*
η_{PV1}	1.25	[55]*	σ_{V1}	0.40	[4, 55]*	γ_{A1}	0.2	[4, 55]
η_{P2}	1.25	[55]*	σ_2	0.40	[4, 55]*	γ_{AV1}	0.2	[4, 55]*
η_{PV2}	1.25	[55]*	σ_{V2}	0.40	[4, 55]*	γ_{A2}	0.2	[4, 55]*
η_{A1}	0.75	[14]	ξ_1	0.40	[4, 55]	γ_{AV2}	0.2	[4, 55]*
η_{AV1}	0.75	[14]*	ξ_{V1}	0.40	[4, 55]*	γ_{H1}	0.0714	[14]
η_{A2}	0.75	[14]*	ξ_2	0.40	[4, 55]*	γ_{HV1}	0.0714	[14]*
η_{AV2}	0.75	[14]*	ξ_{V2}	0.40	[4, 55]*	γ_{H2}	0.0714	[14]*
η_{H1}	0.25	[55]	r	0.6	[14]	γ_{HV2}	0.0714	[14]*
η_{HV1}	0.25	[55]*	r_v	0.6	[14]*	δ_{I1}	0.0008	[14, 55]
η_{H2}	0.25	[55]*	q	0.6	[14]*	δ_{IV1}	0	[14, 55]*
η_{HV2}	0.25	[55]*	q_v	0.6	[14]*	δ_{I2}	0.0015	[14, 55]*
θ_v	1	Assumed	ϕ_1	0.02	[54]*	δ_{IV2}	0.0001	[14, 55]*
θ_c	1	Assumed	ϕ_{V1}	0.02	[54]	δ_{H1}	0.0025	[55]
ψ_1	0	[55]	ϕ_2	0.02	[54]	δ_{HV1}	0.0010	[55]*
ψ_{V1}	0	[55]*	ϕ_{V2}	0.02	[54]	δ_{H2}	0.005	[22, 55]*
ψ_2	0	[55]*	γ_{I1}	0.1	[4, 15]	δ_{HV2}	0.0025	[22, 55]*
ψ_{V2}	0	[55]*	γ_{IV1}	0.1	[4, 15]*	ω_v	0	[55]

* indicates value was adapted from source based on current available data.

464 **6 Appendix B: Computation of \mathcal{R}_{vac}**

465 The associated next generation matrices of the model (A-1) are given by:

$$F_1 = \begin{pmatrix} 0 & 0 & f_1 & f_2 & f_3 & f_4 & f_5 & f_6 & f_7 & f_8 \\ 0 & 0 & f_9 & f_{10} & f_{11} & f_{12} & f_{13} & f_{14} & f_{15} & f_{16} \\ 0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 \\ 0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 \\ 0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 \\ 0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 \\ 0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 \\ 0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 \\ 0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 \\ 0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 \end{pmatrix},$$

466 with entries

$$\begin{aligned} f_1 &= \frac{\beta_1 \eta_{P1} S_U^*}{N^*} \\ f_2 &= \frac{\theta_v \beta_1 \eta_{PV1} S_U^*}{N^*} \\ f_3 &= \frac{\beta_1 S_U^*}{N^*} \\ f_4 &= \frac{\theta_v \beta_1 S_U^*}{N^*} \\ f_5 &= \frac{\beta_1 \eta_{A1} S_U^*}{N^*} \\ f_6 &= \frac{\theta_v \beta_1 \eta_{AV1} S_U^*}{N^*} \\ f_7 &= \frac{\beta_1 \eta_{H1} S_U^*}{N^*} \\ f_8 &= \frac{\theta_v \beta_1 \eta_{HV1} S_U^*}{N^*} \\ f_9 &= \frac{(1 - \varepsilon_v) \beta_1 \eta_{P1} S_V^*}{N^*} \\ f_{10} &= \frac{(1 - \varepsilon_v) \theta_v \beta_1 \eta_{PV1} S_V^*}{N^*} \\ f_{11} &= \frac{(1 - \varepsilon_v) \beta_1 S_V^*}{N^*} \\ f_{12} &= \frac{(1 - \varepsilon_v) \theta_v \beta_1 S_V^*}{N^*} \\ f_{13} &= \frac{(1 - \varepsilon_v) \beta_1 \eta_{A1} S_V^*}{N^*} \\ f_{14} &= \frac{(1 - \varepsilon_v) \theta_v \beta_1 \eta_{AV1} S_V^*}{N^*} \\ f_{15} &= \frac{(1 - \varepsilon_v) \beta_1 \eta_{H1} S_V^*}{N^*} \\ f_{16} &= \frac{(1 - \varepsilon_v) \theta_v \beta_1 \eta_{HV1} S_V^*}{N^*}, \end{aligned}$$

467 and,

$$F_2 = \begin{pmatrix} 0 & 0 & g_1 & g_2 & g_3 & g_4 & g_5 & g_6 & g_7 & g_8 \\ 0 & 0 & g_9 & g_{10} & g_{11} & g_{12} & g_{13} & g_{14} & g_{15} & g_{16} \\ 0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 \\ 0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 \\ 0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 \\ 0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 \\ 0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 \\ 0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 \\ 0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 \\ 0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 \end{pmatrix},$$

with entries

$$\begin{aligned} g_1 &= \frac{\beta_2 \eta_{P2} S_U^*}{N^*} \\ g_2 &= \frac{\theta_c \beta_2 \eta_{PV2} S_U^*}{N^*} \\ g_3 &= \frac{\beta_2 S_U^*}{N^*} \\ g_4 &= \frac{\theta_c \beta_2 S_U^*}{N^*} \\ g_5 &= \frac{\beta_2 \eta_{A2} S_U^*}{N^*} \\ g_6 &= \frac{\theta_c \beta_2 \eta_{AV2} S_U^*}{N^*} \\ g_7 &= \frac{\beta_2 \eta_{H2} S_U^*}{N^*} \\ g_8 &= \frac{\theta_c \beta_2 \eta_{HV2} S_U^*}{N^*} \\ g_9 &= \frac{(1 - \varepsilon_c) \beta_2 \eta_{P2} S_V^*}{N^*} \\ g_{10} &= \frac{(1 - \varepsilon_c) \theta_c \beta_2 \eta_{PV2} S_V^*}{N^*} \\ g_{11} &= \frac{(1 - \varepsilon_c) \beta_2 S_V^*}{N^*} \\ g_{12} &= \frac{(1 - \varepsilon_c) \theta_c \beta_2 S_V^*}{N^*} \\ g_{13} &= \frac{(1 - \varepsilon_c) \beta_2 \eta_{A2} S_V^*}{N^*} \\ g_{14} &= \frac{(1 - \varepsilon_c) \theta_c \beta_2 \eta_{AV2} S_V^*}{N^*} \\ g_{15} &= \frac{(1 - \varepsilon_c) \beta_2 \eta_{H2} S_V^*}{N^*} \\ g_{16} &= \frac{(1 - \varepsilon_c) \theta_c \beta_2 \eta_{HV2} S_V^*}{N^*}. \end{aligned}$$

$$M_1 = \begin{pmatrix} k_1 & 0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 \\ 0 & k_2 & 0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 \\ -\sigma_1 & 0 & k_3 & 0 & 0 & 0 & 0 & 0 & 0 & 0 \\ 0 & -\sigma_{V1} & 0 & k_4 & 0 & 0 & 0 & 0 & 0 & 0 \\ 0 & 0 & -r\xi_1 & 0 & k_5 & 0 & 0 & 0 & 0 & 0 \\ 0 & 0 & 0 & -r_v\xi_{V1} & 0 & k_6 & 0 & 0 & 0 & 0 \\ 0 & 0 & -(1-r)\xi_1 & 0 & 0 & 0 & k_7 & 0 & 0 & 0 \\ 0 & 0 & 0 & -(1-r_v)\xi_{V1} & 0 & 0 & 0 & k_8 & 0 & 0 \\ 0 & 0 & 0 & 0 & -\phi_1 & 0 & 0 & 0 & k_9 & 0 \\ 0 & 0 & 0 & 0 & 0 & -\phi_{V1} & 0 & 0 & 0 & k_{10} \end{pmatrix},$$

468 with entries

$$\begin{aligned} k_1 &= \sigma_1 + \mu \\ k_2 &= \sigma_{V1} + \mu \\ k_3 &= \xi_1 + \mu \\ k_4 &= \xi_{V1} + \mu \\ k_5 &= \phi_1 + \gamma_{I1} + \mu + \delta_{I1} \\ k_6 &= \phi_{V1} + \gamma_{IV1} + \mu + \delta_{IV1} \\ k_7 &= \gamma_{A1} + \mu \\ k_8 &= \gamma_{AV1} + \mu \\ k_9 &= \gamma_{H1} + \mu + \delta_{H1} \\ k_{10} &= \gamma_{HV1} + \mu + \delta_{HV1}, \end{aligned}$$

469 and,

$$M_2 = \begin{pmatrix} k_{11} & 0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 \\ 0 & k_{12} & 0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 \\ -\sigma_2 & 0 & k_{13} & 0 & 0 & 0 & 0 & 0 & 0 & 0 \\ 0 & -\sigma_{V2} & 0 & k_{14} & 0 & 0 & 0 & 0 & 0 & 0 \\ 0 & 0 & -q\xi_1 & 0 & k_{15} & 0 & 0 & 0 & 0 & 0 \\ 0 & 0 & 0 & -q_v\xi_{V2} & 0 & k_{16} & 0 & 0 & 0 & 0 \\ 0 & 0 & -(1-q)\xi_1 & 0 & 0 & 0 & k_{17} & 0 & 0 & 0 \\ 0 & 0 & 0 & -(1-q_v)\xi_{V2} & 0 & 0 & 0 & k_{18} & 0 & 0 \\ 0 & 0 & 0 & 0 & -\phi_2 & 0 & 0 & 0 & k_{19} & 0 \\ 0 & 0 & 0 & 0 & 0 & -\phi_{V2} & 0 & 0 & 0 & k_{20} \end{pmatrix},$$

470 with entries

$$\begin{aligned} k_{11} &= \sigma_2 + \mu \\ k_{12} &= \sigma_{V2} + \mu \\ k_{13} &= \xi_2 + \mu \\ k_{14} &= \xi_{V2} + \mu \\ k_{15} &= \phi_2 + \gamma_{I2} + \mu + \delta_{I2} \\ k_{16} &= \phi_{V2} + \gamma_{IV2} + \mu + \delta_{IV2} \end{aligned}$$

$$\begin{aligned}k_{17} &= \gamma_{A2} + \mu \\k_{18} &= \gamma_{AV2} + \mu \\k_{19} &= \gamma_{H2} + \mu + \delta_{H2} \\k_{20} &= \gamma_{HV2} + \mu + \delta_{HV2}.\end{aligned}$$

Using the approach in [11], the *vaccination reproduction numbers* of the wild-type (strain 1) and variant (strain 2) SARS-CoV-2 strains are found from

$$\mathcal{R}_{vac}^{[1]} = \rho(F_1 M_1^{-1}) \tag{B-1}$$

$$\mathcal{R}_{vac}^{[2]} = \rho(F_2 M_2^{-1}) \tag{B-2}$$

471 respectively, where ρ denotes the spectral radius. The expressions for $\mathcal{R}_{vac}^{[1]}$ and $\mathcal{R}_{vac}^{[2]}$ are given by:

$$\begin{aligned}\mathcal{R}_{vac}^{[1]} &= \frac{\beta_1[\eta_{P1}k_5k_7k_9\sigma_1 + k_7k_9r\xi_1\sigma_1 + \eta_{A1}k_5k_9(1-r)\xi_1\sigma_1 + \eta_{H1}k_7r\xi_1\phi_1\sigma_1] S_U^*}{k_1k_3k_5k_7k_9 N^*} + \\&\quad \frac{(1 - \varepsilon_v)\theta_v\beta_1(Q_1 + Q_2 + Q_3 + Q_4) S_V^*}{k_2k_4k_6k_8k_{10} N^*} \\ \mathcal{R}_{vac}^{[2]} &= \frac{\beta_2[\eta_{P2}k_{15}k_{17}k_{19}\sigma_2 + k_{17}k_{19}q\xi_2\sigma_2 + \eta_{A2}k_{15}k_{19}(1-q)\xi_2\sigma_2 + \eta_{H2}k_{17}q\xi_2\phi_2\sigma_2] S_U^*}{k_{11}k_{13}k_{15}k_{17}k_{19} N^*} + \\&\quad \frac{(1 - \varepsilon_c)\theta_c\beta_2(Q_5 + Q_6 + Q_7 + Q_8) S_V^*}{k_{12}k_{14}k_{16}k_{18}k_{20} N^*},\end{aligned}$$

472 where,

$$\begin{aligned}Q_1 &= \eta_{PV1}k_6k_8k_{10}\sigma_{V1} \\Q_2 &= k_8k_{10}r_v\xi_{V1}\sigma_{V1} \\Q_3 &= \eta_{AV1}k_6k_{10}(1 - r_v)\xi_{V1}\sigma_{V1} \\Q_4 &= \eta_{HV1}k_8r_v\xi_{V1}\phi_{V1}\sigma_{V1} \\Q_5 &= \eta_{PV2}k_{16}k_{18}k_{20}\sigma_{V2} \\Q_6 &= k_{18}k_{20}q_v\xi_{V2}\sigma_{V2} \\Q_7 &= \eta_{AV2}k_{16}k_{20}(1 - q_v)\xi_{V2}\sigma_{V2} \\Q_8 &= \eta_{HV2}k_{18}q_v\xi_{V2}\phi_{V2}\sigma_{V2}.\end{aligned}$$

473 References

- 474 [1] National Institute of Allergies and Infectious Diseases (2020). COVID-19 MERS, & SARS. National Institute
475 of Health. <https://www.niaid.nih.gov/diseases-conditions/covid-19>.
- 476 [2] Centers for Disease Control and Prevention (2021). Long-Term Effects. <https://www.cdc.gov/coronavirus/2019-ncov/long-term-effects.html>.
477
- 478 [3] S.E. Eikenberry, et al (2020). To mask or not to mask: Modeling the potential for face mask use by the general
479 public to curtail the COVID-19 pandemic. *Infectious Disease Modeling* 5, 293-308.
- 480 [4] C.N. Ngonghala, E. Iboi, A.B. Gumel (2020). Could masks curtail the post-lockdown resurgence of covid-19
481 in the US? *Mathematical Biosciences* 329, 108452.
- 482 [5] E.A. Iboi, C.N. Ngonghala, A.B. Gumel (2020). Will an imperfect vaccine curtail the COVID-19 pandemic in
483 the US? *Infectious Disease Modelling* 5, 510-524.

- 484 [6] Mayo Clinic (2021). COVID-19 vaccines: Get the facts. <https://www.mayoclinic.org/coronavirus-vaccine/art-20484859>.
485
- 486 [7] P. van den Driessche and J. Watmough, "Reproduction numbers and sub-threshold endemic equilibria for
487 compartmental models of disease transmission," *Mathematical Biosciences* **180**, 29-48 (2002).
- 488 [8] O. Diekmann, J. A. P. Heesterbeek, and J. A. Metz, "On the definition and the computation of the basic
489 reproduction ratio R_0 in models for infectious diseases in heterogenous populations," *Journal of Mathematical
490 Biology* **28**, 365-382 (1990).
- 491 [9] R.M. Anderson and R.M. May, "Vaccination and herd immunity to infectious diseases," *Nature* 318, 323-329
492 (1985).
- 493 [10] R M. Anderson, "The concept of herd immunity and the design of community-based immunization pro-
494 grammes," *Vaccine* 10, 928-935 (1992).
- 495 [11] A.B. Gumel, B. Song, "Existence of Multiple-Stable Equilibria for a Multi-Drug-Resistant Model of My-
496 cobacteria," *Mathematical Biosciences and Engineering* **5:3**, 437-455 (2008).
- 497 [12] M.D. McKay, R.J. Beckan, W.J. Conover (1979). A Comparison of Three Methods for Selecting Values of
498 Input Variables in the Analysis of Output from a Computer Code. *Technometrics*, 21:2, 239-245.
- 499 [13] S.M. Blower, H. Dowlatabadi (1994). Sensitivity and Uncertainty Analysis of Complex Models of Disease
500 Transmission: an HIV Model, as an Example. *International Statistical Review*. 62:2, 229-243.
- 501 [14] Centers for Disease Control and Prevention (2021). Pandemic Planning Scenarios. <https://www.cdc.gov/coronavirus/2019-ncov/hcp/planning-scenarios.html>.
502
- 503 [15] C.N. Ngonghala, et al. (2020). Mathematical assessment of the impact of non-pharmaceutical interventions
504 on curtailing the 2019 novel Coronavirus. *Mathematical Biosciences* 325.
- 505 [16] United States Food and Drug Administration (2021). Coronavirus (COVID-19) Up-
506 date: FDA Issues Policies to Guide Medical Product Developers Addressing Virus
507 Variants. [https://www.fda.gov/news-events/press-announcements/
508 coronavirus-covid-19-update-fda-issues-policies-guide-medical-product-developers-a](https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-issues-policies-guide-medical-product-developers-a)
- 509 [17] K Wu, et al. (2021). mRNA-1273 vaccine induces neutralizing antibodies against spike mutants from
510 global SARS-CoV-2 variants. *Biorxiv*. [https://www.biorxiv.org/content/10.1101/2021.01.
511 25.427948v1.full](https://www.biorxiv.org/content/10.1101/2021.01.25.427948v1.full).
- 512 [18] A.J. Greaney et al (2021). Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain
513 that affect recognition by polyclonal human plasma antibodies. *Cell Host & Microbe*. 29:3, P463-476.
- 514 [19] Centers for Disease Control and Prevention (2021). Emerging SARA-CoV-2 Variants.
515 [https://www.cdc.gov/coronavirus/2019-ncov/science/science-briefs/
516 scientific-brief-emerging-variants.html?CDC_AA_refVal=https%3A%2F%
517 2Fwww.cdc.gov%2Fcoronavirus%2F2019-ncov%2Fmore%2Fscience-and-research%
518 2Fscientific-brief-emerging-variants.html](https://www.cdc.gov/coronavirus/2019-ncov/science/science-briefs/scientific-brief-emerging-variants.html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fcoronavirus%2F2019-ncov%2Fmore%2Fscience-and-research%2Fscientific-brief-emerging-variants.html).
- 519 [20] B. Korber et al. (2020) Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity
520 of the COVID-19 Virus. *Cell* 182, 812-827.
- 521 [21] E. Volz, et al. (2021). Transmission of SARS-CoV-2 Lineage B.1.1.7 in England: Insights from linking epi-
522 demiological and genetic data. *MedRxiv*. [https://www.medrxiv.org/content/10.1101/2020.
523 12.30.20249034v2](https://www.medrxiv.org/content/10.1101/2020.12.30.20249034v2).

- 524 [22] P. Horby, et al. (2021). NERVTAG note on B.1.1.7 severity for SAGE. New and Emerging Respiratory Virus
525 threads Advisory Group.
- 526 [23] N.G. Davies, et al. (2020). Estimated transmissible and severity of novel SARS-CoV-2 Variant of Con-
527 cern 202012/01 in England. medRxiv. [https://cmmid.github.io/topics/covid19/reports/
528 uk-novel-variant/2020_12_23_Transmissibility_and_severity_of_VOC_202012_
529 01_in_England.pdf](https://cmmid.github.io/topics/covid19/reports/uk-novel-variant/2020_12_23_Transmissibility_and_severity_of_VOC_202012_01_in_England.pdf).
- 530 [24] Colorado Governor Jared Polis (2020). Gov. Polis and State Public Health Officials Announce First
531 Case of COVID Variant of COVID-19 in Colorado. [https://www.colorado.gov/governor/news/
532 3856-gov-polis-and-state-public-health-officials-announce-first-case-covid-variant](https://www.colorado.gov/governor/news/3856-gov-polis-and-state-public-health-officials-announce-first-case-covid-variant)
- 533 [25] South Carolina Department of Health and Environmental Control (2021). South Carolina
534 Public Health Officials Detect Nation's First Known Cases of the COVID-19 Variant Origin-
535 ally Detected in South Africa. [https://scdhec.gov/index.php/news-releases/
536 south-carolina-public-health-officials-detect-nations-first-known-cases-covid-19](https://scdhec.gov/index.php/news-releases/south-carolina-public-health-officials-detect-nations-first-known-cases-covid-19).
- 537 [26] Minnesota Department of Health (2021). MDH lab testing confirms nation's first known COVID-19 case
538 associated with Brazil P.1 variant. [https://www.health.state.mn.us/news/pressrel/2021/
539 covid012521.html](https://www.health.state.mn.us/news/pressrel/2021/covid012521.html).
- 540 [27] United States Food and Drug Administration (2020). FDA Takes Key Action in
541 Fight Against COVID-19 By Issuing Emergency Use Authorization for First COVID-
542 19 Vaccine. [https://www.fda.gov/news-events/press-announcements/
543 fda-takes-key-action-fight-against-covid-19-issuing-emergency-use-authorization-fi](https://www.fda.gov/news-events/press-announcements/fda-takes-key-action-fight-against-covid-19-issuing-emergency-use-authorization-fi)
- 544 [28] United States Food and Drug Administration (2020). FDA Briefing Document Pfizer-BioNTech COVID-19
545 Vaccine. <https://www.fda.gov/media/144245/download>.
- 546 [29] United States Food and Drug Administration (2020). FDA Briefing Document Moderna COVID-19 Vaccine.
547 <https://www.fda.gov/media/144434/download>.
- 548 [30] United States Food and Drug Administration (2021). FDA Issues Emergency Use Authorization
549 for Third COVID-19 Vaccine. [https://www.fda.gov/news-events/press-announcements/
550 fda-issues-emergency-use-authorization-third-covid-19-vaccine](https://www.fda.gov/news-events/press-announcements/fda-issues-emergency-use-authorization-third-covid-19-vaccine).
- 551 [31] Center for Systems Science and Engineering at Johns Hopkins University. (2021). COVID-19. Github repos-
552 itory. <https://github.com/CSSEGISandData/COVID-19>.
- 553 [32] Bloomberg Covid-19 Vaccine Tracker Open Data. (2021). Github repository. [https://github.com/
554 BloombergGraphics/covid-vaccine-tracker-data](https://github.com/BloombergGraphics/covid-vaccine-tracker-data).
- 555 [33] Bloomberg, (2021). More Than 2.23 Billion Shots Given: Covid-19 Tracker. [https://www.bloomberg.
556 com/graphics/covid-vaccine-tracker-global-distribution/](https://www.bloomberg.com/graphics/covid-vaccine-tracker-global-distribution/).
- 557 [34] Centers for Disease Control and Prevention (2021). The Advisory Committee on Immunization Practices'
558 Updated Interim Recommendation for Allocation of COVID-19 Vaccine – United States, December 2020.
559 Morbidity and Mortality Weekly Report (MMWR). [https://www.cdc.gov/mmwr/volumes/69/wr/
560 mm695152e2.htm?s_cid=mm695152e2_w](https://www.cdc.gov/mmwr/volumes/69/wr/mm695152e2.htm?s_cid=mm695152e2_w).
- 561 [35] Centers for Disease Control and Prevention, (2021). Variant Proportions. [https://covid.cdc.gov/
562 covid-data-tracker/#variant-proportions](https://covid.cdc.gov/covid-data-tracker/#variant-proportions).

- 563 [36] Centers for Disease Control and Prevention (2021). SARS-CoV-2 Variant Classifications and Def-
564 initions. https://www.cdc.gov/coronavirus/2019-ncov/variants/variant-info.html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fcoronavirus%2F2019-ncov%2Fcases-updates%2Fvariant-surveillance%2Fvariant-info.html
- 567 [37] United States Census Bureau, (2020). National Demographic Analysis Tables: 2020. <https://www.census.gov/data/tables/2020/demo/popest/2020-demographic-analysis-tables.html>.
- 570 [38] X. Xie, et al. (2021). Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K, and N501Y variants by
571 BNT162b2 vaccine-elicited sera. bioRxiv. <https://www.biorxiv.org/content/10.1101/2021.01.27.427998v1.full.pdf+html>.
- 573 [39] D.T. Skelly, et al. (2021). Vaccine-inuced immunity provides more robust heterotypic immunity than
574 natural infection to emerging SARS-CoV-2 variants of concern. Research Square. <https://www.researchsquare.com/article/rs-226857/v1>.
- 576 [40] D. Ducey, (2021). State of Arizona Executive Order 2021-06. March 25, 2021.
- 577 [41] D. Ducey, (2020). State of Arizona Executive Order 2020-18.
- 578 [42] M. Polletta, A. Oxford (2020). Arizona governor issues 'stay-at-home' order; will take effect close of business
579 Tuesday. azcentral. <https://www.azcentral.com/story/news/local/arizona-health/2020/03/30/arizona-coronavirus-stay-home-order-issued-gov-doug-ducey/5088109002/>.
- 582 [43] FOX 10 Phoenix, (2020). LIST: Arizona cities with face mask requirements. <https://www.fox10phoenix.com/news/list-arizona-cities-with-face-mask-requirements>.
- 584 [44] G. Whitmer, (2020). Executive Order No. 2020-42. State of Michigan Office of the Governor.
- 585 [45] G. Whitmer, (2020). Executive Order No. 2020-60. State of Michigan Office of the Governor.
- 586 [46] G. Whitmer, (2020). Executive Order No. 2020-110. State of Michigan Office of the Governor. https://www.michigan.gov/coronavirus/0,9753,7-406-98178_98455-550215--,00.html
- 588 [47] R. Gordon, (2020). Gatherings and Face Mask Order. Michigan Department of Health and Human Services.
- 589 [48] G. Abbott, (2020). Executive Order GA 14.
- 590 [49] G. Abbott, (2020). Executive Order GA 29.
- 591 [50] G. Abbott, (2020). Executive Order GA 34.
- 592 [51] M.E. Klas, S. Contorno, (2020). Florida Gov. Ron DeSantis issues statewide stay-at-home
593 order. Tampa Bay Times. <https://www.tampabay.com/news/health/2020/04/01/florida-gov-ron-desantis-issues-statewide-stay-at-home-order/>.
- 594 [52] WESH 2, (2020). Florida governor extends order suspending COVID-19 related enforcement fines.
595 <https://www.wesh.com/article/florida-covid-19-mask-fines-order-extended/34778032>.
- 596 [53] E.H. Elbasha, A.B. Gumel (2006). Theoretical Assessment of Public Health Impact of Imperfect Prophylactic
597 HIV-1 Vaccines with Therapeutic Benefits. Bulletin of Mathematical Biology. 68: 577-614.
- 600 [54] A.B. Gumel, E.A. Iboi, c.N. Ngonghala, E.H. Elbasha (2021). A primer on using mathematics to understand
601 COVID-19 dynamics: Modeling, analysis, and simulations. Infectious Disease Modelling 6, 1-21.

- 602 [55] A.B. Gumel, E.A. Iboi, C.N. Ngonghala, G.A. Ngwa (2021). Mathematical assessment of the roles of vaccina-
603 tion and non-pharmaceutical interventions on COVID-19 dynamics: a multigroup modeling approach. medRxiv.
- 604 [56] J. Hellewell et al. (2020). Feasibility of controlling COVID-19 outbreaks by isolation of cases and contacts.
605 The Lancet Global Health, 8, E488-E496.
- 606 [57] N. Hoertel et al. (2020). A stochastic agent-based model of the sars-cov-2 epidemic in France. Nature
607 Medicine, 26, 1417-1421.
- 608 [58] A.J. Kucharski et al. (2020). Early dynamics of transmission and control of covid-19: A mathematical mod-
609 elling study. The Lancet Infectious Diseases, 20, 553-558.
- 610 [59] Institute for Health Metrics and Evaluation. (2020). Forecasting COVID-19 impact on hospital bed-days,
611 ICU-days, ventilator-days, and deaths by US state in the next 4 months.
- 612 [60] A. Tariq et al. (2020). Real-time monitoring the transmission potential of COVID-19 in Singapore, March
613 2020. BMC Medicine, 18, 1-14.
- 614 [61] A. Srivastava and G. Chowell (2020). Understanding spatial heterogeneity of COVID-19 pandemic using
615 shape analysis of growth rate curves. MedRxiv.
- 616 [62] J.A. Firth, J. Hellewell, P. Klepac, S. Kissler (2020). Using a real-world network to model localized covid-19
617 control strategies. Nature Medicine, 1-22.
- 618 [63] S. Thurner, P. Klimek, R. Hanel (2020). A network-based explanation of why most covid-19 infection curves
619 are linear. Proceedings of the National Academy of Sciences, 117(37), 22684-22689.
- 620 [64] L. Xue et al. (2020). A data-driven network model for the emerging covid-19 epidemics in Wuhan, Toronto,
621 and Italy. Mathematical Biosciences, 326, 108391.
- 622 [65] E. Cuevas (2020). An agent-based model to evaluate the covid-19 transmission risks in facilities. Computers
623 in Biology and Medicine. 121, 103827
- 624 [66] N.M. Ferguson et al. (2020). Impact of non-pharmaceutical interventions (NPIs) to reduce COVID-19 mor-
625 tality and healthcare demand. London: Imperial College COVID-19 Response Team.
- 626 [67] H.W. Hethcote (2000). The mathematics of infectious diseases. SIAM Review 42, 599-653.
- 627 [68] R.G. McLeod, J.F. Brewster, A.B. Gumel, D.A. Slonowsky (2006). Sensitivity and Uncertainty Analyses for a
628 SARS Model with Time-Varying Inputs and Outputs. Mathematical Biosciences and Engineering, 3:3, 527-544.
- 629 [69] United States Food and Drug Administration. Pfizer-BioNTech COVID-19 Vac-
630 cine. [https://www.fda.gov/emergency-preparedness-and-response/
631 coronavirus-disease-2019-covid-19/pfizer-biontech-covid-19-vaccine](https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/pfizer-biontech-covid-19-vaccine).
- 632 [70] Center for Disease Control and Prevention (2021). COVID Data Tracker. [https://covid.cdc.gov/
633 covid-data-tracker/#datatracker-home](https://covid.cdc.gov/covid-data-tracker/#datatracker-home).
- 634 [71] J. Greenhalgh (2021). The Highly Contagious Delta Variant is On
635 The Rise In The U.S. National Public Radio. [https://www.npr.org/
636 sections/coronavirus-live-updates/2021/06/08/1004597294/
637 the-highly-contagious-delta-variant-of-covid-is-on-the-rise-in-the-u-s](https://www.npr.org/sections/coronavirus-live-updates/2021/06/08/1004597294/the-highly-contagious-delta-variant-of-covid-is-on-the-rise-in-the-u-s).
- 638 [72] L.J. Abu-Raddad, A.A. Butt, (2021). Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7
639 and B.1.351 Variants. New England Journal of Medicine. DOI: 10.1056/NEJMc2104974